D-L Ou

Learn More
BACKGROUND Sorafenib is the only drug approved for the treatment of hepatocellular carcinoma (HCC). The bioenergetic propensity of cancer cells has been correlated to anticancer drug resistance, but such correlation is unclear in sorafenib resistance of HCC. METHODS Six sorafenib-naive HCC cell lines and one sorafenib-resistant HCC cell line (Huh-7R;(More)
  • 1